Creon patent expiration?

I can help, but I need a bit more detail because “Creon” has multiple strengths/products and multiple patent families, each expiring on different dates depending on country.

Quick questions:

1. What country/market are you asking about? (e.g., US, EU, UK, Canada, India)
2. Which product exactly: Creon (pancrelipase)? If you know it—what strength/dose (e.g., 10,000 / 25,000 / 36,000)?
3. Do you mean patent expiration specifically, or also exclusivity (FDA exclusivity periods, EU SPC term, etc.)?

If you tell me those, I can give you the likely patent expiration date(s) and what that means for generic/authorized generic timing.

In the meantime, a useful note: many “Creon generic availability” timelines hinge less on a single patent and more on:

• Patent expiry date(s)
• Any remaining regulatory exclusivities (country-specific)
• Whether bios/generics are blocked by patents in the same “family”
• SPCs (EU/UK) and pediatric/other extensions